IA
BIO icon

IndexIQ Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

IndexIQ Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$2K Buy
+3
New +$1.81K ﹤0.01% 1278

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

IndexIQ Advisors's BIO Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in Bio-Rad Laboratories Class A (BIO) in Q1 2022: 3 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1278 among its holdings.

515 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

  • IndexIQ Advisors held 3 shares of Bio-Rad Laboratories Class A worth $2K as of Q1 2022.
  • Bio-Rad Laboratories Class A was a new IndexIQ Advisors position in Q1 2022.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #1278 holding.
  • 515 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.